Literature DB >> 17030587

Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases.

Roberto Monastero, Cecilia Camarda, Carmela Pipia, Rosolino Camarda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17030587      PMCID： PMC2117848          DOI： 10.1136/jnnp.2006.096420

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

Review 1.  Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.

Authors:  Stuart A Lipton
Journal:  Nat Rev Drug Discov       Date:  2006-02       Impact factor: 84.694

Review 2.  Memantine for dementia.

Authors:  R McShane; A Areosa Sastre; N Minakaran
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

3.  Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.

Authors:  B H Ridha; K A Josephs; M N Rossor
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

4.  Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry.

Authors:  R L Hamilton
Journal:  Brain Pathol       Date:  2000-07       Impact factor: 6.508

5.  Visual hallucinations and delirium during treatment with amantadine (Symmetrel).

Authors:  J U Postma; W Van Tilburg
Journal:  J Am Geriatr Soc       Date:  1975-05       Impact factor: 5.562
  5 in total
  10 in total

Review 1.  Homeostatic disinhibition in the aging brain and Alzheimer's disease.

Authors:  Marc Gleichmann; Vivian W Chow; Mark P Mattson
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

2.  [Antidementia drugs--response or non-response?].

Authors:  H Förstl
Journal:  Internist (Berl)       Date:  2008-03       Impact factor: 0.743

3.  Advances in the treatment of visual hallucinations in neurodegenerative diseases.

Authors:  Daniel Collerton; John-Paul Taylor
Journal:  Future Neurol       Date:  2013-07

Review 4.  Alternatives to atypical antipsychotics for the management of dementia-related agitation.

Authors:  Michael J Passmore; David M Gardner; Yvette Polak; Kiran Rabheru
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

5.  Effect of memantine on resting state default mode network activity in Alzheimer's disease.

Authors:  Marco Lorenzi; Alberto Beltramello; Nicola B Mercuri; Elisa Canu; Giada Zoccatelli; Francesca B Pizzini; Franco Alessandrini; Maria Cotelli; Sandra Rosini; Daniela Costardi; Carlo Caltagirone; Giovanni B Frisoni
Journal:  Drugs Aging       Date:  2011-03-01       Impact factor: 3.923

6.  Parkinson's psychosis.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Curr Treat Options Neurol       Date:  2010-05       Impact factor: 3.598

Review 7.  Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease.

Authors:  Nathan Herrmann; Serge Gauthier
Journal:  CMAJ       Date:  2008-12-02       Impact factor: 8.262

Review 8.  Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  CNS Spectr       Date:  2008-03       Impact factor: 3.790

Review 9.  Dementia-related psychosis and the potential role for pimavanserin.

Authors:  Jeffery L Cummings; D P Devanand; Stephen M Stahl
Journal:  CNS Spectr       Date:  2020-08-19       Impact factor: 3.790

10.  Memantine in moderately-severe-to-severe Alzheimer's disease: a postmarketing surveillance study.

Authors:  Francesca Clerici; Nicola Vanacore; Antonietta Elia; Stefania Spila-Alegiani; Simone Pomati; Roberto Da Cas; Roberto Raschetti; Claudio Mariani
Journal:  Drugs Aging       Date:  2009       Impact factor: 4.271
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.